Welcome to our dedicated page for PYXUS INTERNATIONAL SEC filings (Ticker: PYYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PYXUS INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PYXUS INTERNATIONAL's regulatory disclosures and financial reporting.
Pyxus International, Inc. (PYYX) reported an equity compensation grant to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock. The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated earning if service ends earlier.
Actual vesting is further contingent on the earliest of three events: March 31, 2031; a qualifying Change in Control under the company’s 2020 Incentive Plan; or Pyxus common stock being listed for trading on a U.S. or approved foreign securities exchange.
Pyxus International, Inc. furnished an 8-K announcing it issued a press release with operating and financial results for the three and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is furnished, not filed under Section 18 of the Exchange Act. The report lists no securities registered under Section 12(b). The date of the report and press release is November 12, 2025.
Pyxus International filed its 10‑Q reporting Q2 FY2026 results. Sales and other operating revenues were $570.2 million, up 0.7% year over year, as higher volumes and processing revenues offset lower average sales prices. Gross margin improved to 15.4% from 13.3%, and operating income rose to $46.7 million. After $37.9 million of interest expense and $10.3 million of income tax expense, the company reported a net loss of $0.9 million, or $(0.03) per share.
For the first six months, sales were $1,079.0 million, down 10.2%, with a net loss of $16.7 million. Working capital peaked seasonally: inventories increased to $1,135.2 million, and notes payable rose to $908.0 million. Net cash used in operating activities was $580.9 million, reflecting procurement in Africa and South America and timing of shipments. Long‑term debt was $455.3 million and the company remained in compliance with covenants.
The ABL Credit Facility was amended on May 12, 2025 to increase commitments to $150 million and extend maturity to 2030, and two receivables securitization programs remained active. As of October 31, 2025, common shares outstanding were 24,607,791.